Incyte Q4 Earnings Call Highlights

Core Insights - Incyte reported strong financial performance for 2025, with total revenue of $5.14 billion, up 21%, and core product sales excluding Jakafi increasing by 53% to $1.26 billion, driven by OPZELURA, Niktimvo, and MONJUVI [4][2][3] Financial Performance - Jakafi sales reached $3.093 billion in 2025, reflecting an 11% increase year-over-year, with fourth quarter sales of $828 million, up 7% [1][4] - Total revenue for the fourth quarter was $1.51 billion, a 28% increase compared to the previous year, with net product sales of $1.22 billion, up 20% [2] - Management expects 2026 revenue guidance of $4.77 billion to $4.94 billion, with core business sales excluding Jakafi projected to be $1.57 billion to $1.69 billion, indicating approximately 30% growth at the midpoint [10] Product Performance - OPZELURA achieved fourth quarter net sales of $207 million, up 28%, and full-year net sales of $678 million, up 33%, driven by increased penetration in U.S. atopic dermatitis and vitiligo [5][6] - Hematology and oncology products generated fourth quarter net sales of $187 million, up 121%, and full-year sales of $583 million, up 83%, supported by Niktimvo, MONJUVI, and ZYNYZ [6] Pipeline and Development - The company is accelerating late-stage development with 14 pivotal trials across seven assets expected by the end of 2026, including anticipated FDA acceptance for povorcitinib in hidradenitis suppurativa in Q1 2026 [3][9] - Recent approvals include MONJUVI for follicular lymphoma and ZYNYZ for squamous cell anal carcinoma, with ongoing submissions for Jakafi XR and OPZELURA [8] Strategic Focus - Management emphasized 2026 as an "inflection point," focusing on execution across product launches and multiple Phase III programs, aiming to create a strong growth trajectory post-2029 [13] - The company plans to enhance formulary access for Jakafi XR, targeting a 10% to 30% conversion rate over time [5]